C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 471/04 (2006.01) A61K 31/4375 (2006.01) A61P 19/00 (2006.01)
Patent
CA 2421652
The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as .alpha.v.beta.3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis.
L'invention concerne des nouveaux composés formés par conversion métabolique de composés correspondant à la formule développée (1), ainsi que des compositions pharmaceutiques contenant de tels composés, de même que l'utilisation de ces composés en tant qu'antagonistes du récepteur de l'intégrine .alpha.v.beta.3. Les composés de l'invention sont utiles pour inhiber la résorption osseuse, la resténose, l'angiogenèse, la rétinopathie diabétique, la dégénérescence maculaire, l'arthrite inflammatoire, le cancer, et la croissance tumorale métastatique. Ces composés sont notamment utiles pour inhiber la résorption osseuse et pour traiter et prévenir l'ostéoporose.
Arison Byron H.
Cui Donghui
Duggan Mark E.
Fang Xiaojun
Halczenko Wasyl
Merck And Co. Inc.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Alpha v integrin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha v integrin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha v integrin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1890122